These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 20976730

  • 1. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment.
    Yeh CN, Chen TW, Tseng JH, Liu YY, Wang SY, Tsai CY, Chiang KC, Hwang TL, Jan YY, Chen MF.
    J Surg Oncol; 2010 Nov 01; 102(6):599-603. PubMed ID: 20976730
    [Abstract] [Full Text] [Related]

  • 2. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
    Zhou Y, Hou YY, Tan YS, Lu SH, Hou J, Liu JL, Qin J, Shen KT, Sun YH.
    Zhonghua Zhong Liu Za Zhi; 2009 Aug 01; 31(8):597-601. PubMed ID: 20021947
    [Abstract] [Full Text] [Related]

  • 3. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P, Debiec-Rychter M, Nowecki ZI, Wozniak A, Michej W, Limon J, Siedlecki JA, Jerzak Vel Dobosz A, Grzesiakowska U, Nasierowska-Guttmejer A, Sygut J, Nyckowski P, Krawczyk M, Ruka W.
    Med Sci Monit; 2007 Nov 01; 13(11):CR515-522. PubMed ID: 17968300
    [Abstract] [Full Text] [Related]

  • 4. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
    Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK.
    Oncology; 2009 Nov 01; 76(5):326-32. PubMed ID: 19307738
    [Abstract] [Full Text] [Related]

  • 5. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
    Kang HJ, Ryu MH, Kim KM, Park YS, Choi J, Ryoo BY, Kim WH, Im SA, Bang YJ, Park SH, Lee JH, Chung IJ, Bae HI, Kim JG, Lee KH, Song HS, Kwon HC, Baek JH, Shin DB, Lee KE, Kang YK.
    Acta Oncol; 2012 Apr 01; 51(4):528-36. PubMed ID: 22150077
    [Abstract] [Full Text] [Related]

  • 6. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
    Loughrey MB, Trivett M, Beshay V, Dobrovic A, Kovalenko S, Murray W, Lade S, Turner H, McArthur GA, Zalcberg J, Waring PM.
    Histopathology; 2006 Jul 01; 49(1):52-65. PubMed ID: 16842246
    [Abstract] [Full Text] [Related]

  • 7. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN, Chen TW, Lee HL, Liu YY, Chao TC, Hwang TL, Jan YY, Chen MF.
    Ann Surg Oncol; 2007 Mar 01; 14(3):1123-8. PubMed ID: 17195905
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
    Mussi C, Schildhaus HU, Gronchi A, Wardelmann E, Hohenberger P.
    Clin Cancer Res; 2008 Jul 15; 14(14):4550-5. PubMed ID: 18628470
    [Abstract] [Full Text] [Related]

  • 9. Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.
    Benjamin RS, Blanke CD, Blay JY, Bonvalot S, Eisenberg B.
    Oncologist; 2006 Jan 15; 11(1):9-20. PubMed ID: 16401709
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pathology of gastrointestinal stromal tumors.
    Hirota S, Isozaki K.
    Pathol Int; 2006 Jan 15; 56(1):1-9. PubMed ID: 16398673
    [Abstract] [Full Text] [Related]

  • 14. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
    Wardelmann E, Merkelbach-Bruse S, Büttner R, Schildhaus HU.
    Verh Dtsch Ges Pathol; 2007 Jan 15; 91():165-8. PubMed ID: 18314611
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.
    Ménard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C, Nonn C, Chaput N, Taïeb J, Delahaye NF, Flament C, Emile JF, Le Cesne A, Zitvogel L.
    Cancer Res; 2009 Apr 15; 69(8):3563-9. PubMed ID: 19351841
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A, den Bakker MA, van Geel AN, Eggermont AM, Sleijfer S, Verweij J, de Wilt JH, Verhoef C.
    Anticancer Drugs; 2008 Jul 15; 19(6):607-12. PubMed ID: 18525320
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.